Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Multiple sclerosis: Cognitive status declines on warmer days in patients with multiple sclerosis.
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.
Cognitive Impairment Has a Strong Relation to Nonsomatic Symptoms of Depression in Relapsing-Remitting Multiple Sclerosis.
The genetics of multiple sclerosis: an up-to-date review.
Suppression of Experimental Autoimmune Optic Neuritis by the Novel Agent Fingolimod.
Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets.
MARINOL®
Is natalizumab overshooting its rebound?
Fine-tuning the central nervous system: microglial modelling of cells and synapses.
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Lobular panniculitis and lipoatrophy of the thighs with interferon-ß1a for intramuscular injection in a patient with multiple sclerosis.
Effects of dual-task balance training on postural performance in patients with Multiple Sclerosis: A double-blind, randomized controlled pilot trial.
Identification of shared genes and pathways: a comparative study of multiple sclerosis susceptibility, severity and response to interferon Beta treatment.
Yoga for multiple sclerosis: a systematic review and meta-analysis.
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis.
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
Natalizumab treatment reduces endothelial activity in MS patients.
"Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis.
Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis.
Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study.
Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.

Pages